Glassia

BIOLOGICAL4 trials

Sponsors

Baxalta now part of Shire, Impatients N.V. trading as myTomorrows, Octapharma

Conditions

Acute Graft-Versus-Host Reaction Following Bone Marrow TransplantAcute-graft-versus-host DiseaseAlpha 1-Antitrypsin DeficiencyAlpha-1 Protease Inhibitor DeficiencyAlpha-1 Proteinase InhibitorAlpha1-antitrypsin DeficiencyGraft Versus Host DiseaseGraft Vs Host Disease

Phase 2

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

TerminatedNCT02956122

Baxalta now part of ShireGraft Versus Host Disease

Start: 2017-04-26End: 2018-05-03Updated: 2021-01-13

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

WithdrawnNCT03385395

OctapharmaAlpha 1-Antitrypsin Deficiency

Start: 2018-07-31End: 2019-12-31Updated: 2018-04-10

Phase 3

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

CompletedNCT02525861

Baxalta now part of ShireAlpha1-antitrypsin Deficiency

Start: 2016-03-08End: 2020-07-29Updated: 2021-10-14

Unknown Phase

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Impatients N.V. trading as myTomorrowsAcute-graft-versus-host Disease, Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Alpha 1-Antitrypsin Deficiency +5

Updated: 2020-10-05